Read on Twitter
Thankful to Singapore for surveillance systems that allow for the detailed studies required to truly assess the relative transmission risk of asymptomatic vs symptomatic cov-2 
, which they find to be much higher in those who develop symptoms /1
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32651-9/fulltext
, which they find to be much higher in those who develop symptoms /1https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32651-9/fulltext
couple points:
1. Use of serology to stratify recency infection was a nice addition
2. A better description of asymptomatic definition would be helpful. We go through this thorny issue here @mugecevik @EricMeyerowitz @BogochIsaac @nicolamlow
/2 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30837-9/fulltext
1. Use of serology to stratify recency infection was a nice addition
2. A better description of asymptomatic definition would be helpful. We go through this thorny issue here
@mugecevik @EricMeyerowitz @BogochIsaac @nicolamlow /2 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30837-9/fulltext
This is consistent with limited data summarized in several nice recent systematic reviews:
1. Transmission potential appears lower in asymptomatic infection from @nicolamlow and team https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508369/
/3
1. Transmission potential appears lower in asymptomatic infection from @nicolamlow and team https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508369/
/3
2. Suggestion of faster viral load clearance in asymptomatic infection from @mugecevik et al
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30172-5/fulltext
/4
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(20)30172-5/fulltext
/4
Why does this matter?
There is a prevailing narrative right now that the 90%+ protection from symptomatic cov-2 by the mrna vaccines might not sizably reduce infection or transmission
/5
There is a prevailing narrative right now that the 90%+ protection from symptomatic cov-2 by the mrna vaccines might not sizably reduce infection or transmission
/5
These studies strongly suggest that even if vaccines do not reduce risk of infection, they will substantially reduce risk of transmission
/end
/end
